Survey to help Canadian CLL (chronic lymphocytic leukemia) Patients
The Canadian regulatory system for the approval of new medicines is very similar to Australia, but different than in the USA. Lymphoma Canada It is currently preparing submissions to their decision makers for the following treatments:
· Ibrutinib (Imbruvica) for patients with previously untreated CLL for whom fludarabine based treatment is considered inappropriate
· Ventetoclax (ABT – 199) for patients with relapsed/refractory CLL
Lymphoma Canada like Lymphoma Australia can survey patients and caregivers to provide data to regulators on the side effects and quality of life experienced by those on current therapies and how a new therapy may improve the quality of life for patients. This information can then help the regulators better understand the value of new therapies for patients and their families.
HOW CAN ANY CLL PATIENTS HELP?
Please complete the survey below for Lymphoma Canada. You do not need to live in Canada to complete this survey.
The survey will be open until midnight (Pacific Time- Canada) on Wednesday, April 20th and should only take 10 minutes of your time.
You may access the survey by clicking the link below.